TROP2

Assets acting on this target.

Class
TROP2-directed
Pathway
TROP2-targeted delivery of monomethyl auristatin E cytotoxic payload to tumor cells

TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein expressed at low levels on many normal epithelial tissues but markedly overexpressed on the surface of numerous solid tumors, including cancers of the breast, lung, bladder, and gastrointestinal tract. Because of this differential expression, TROP2 serves less as a driver of tumor growth to be blocked and more as a docking point for targeted drug delivery. Antibody-drug conjugates (ADCs) exploit this by linking a monoclonal antibody that recognizes TROP2 to a cytotoxic payload, in this case monomethyl auristatin E (MMAE), a potent inhibitor of microtubule assembly. Upon binding, the antibody-payload complex is internalized by the tumor cell, and the payload is released intracellularly, causing cell-cycle arrest and death. This strategy aims to concentrate a highly toxic chemotherapeutic agent within tumor tissue while limiting systemic exposure, broadening the therapeutic window compared with administering the cytotoxic agent alone. TROP2-directed ADCs are being explored across a wide range of epithelial malignancies where the antigen is commonly overexpressed, reflecting a strategy of using tumor-selective surface markers as delivery vehicles rather than as direct signaling targets whose inhibition alone would be expected to slow tumor growth.

By indication

Related mechanisms

TROP2 drugs compared

8 drugs, stage by indication
8 drugs acting on TROP2: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Datopotamab DeruxtecanAstraZeneca, Daiichi Sankyoantibody-drug conjugateApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Approved in Non-Small Cell Lung Cancer; Phase 3 in Urothelial Carcinoma
Sacituzumab GovitecanGilead Sciencesantibody-drug conjugateApprovedApproved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Endometrial Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Urothelial Carcinoma
Sacituzumab TirumotecanMerck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.antibody-drug conjugatePhase 3Phase 3 in Bladder Cancer; Phase 3 in Breast Cancer; Phase 3 in Cervical Cancer; Phase 3 in Endometrial Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Ovarian Cancer
Sacituzumab drozuntecanBioNTech, DualityBio Inc.antibody-drug conjugatePhase 2Not recorded
Tizetatug rezetecanJiangsu Hengrui Pharmaceuticalsantibody-drug conjugatePhase 2Phase 2 in Non-Small Cell Lung Cancer
BL-M02D1Sichuan Baili Pharmaceuticalantibody-drug conjugatePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
LCB84Janssen, LigaChem Biosciences, Inc.antibody-drug conjugatePhase 1/2Not recorded
MT-302CREATE Medicinesgene therapyPhase 1Not recorded

← all mechanisms